8-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 5, 2009

Opexa Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Texas
(State or Other Jurisdiction of Incorporation)

001-33004	76-0333165
(Commission File Number)	(I.R.S. Employer Identification No.)

2635 N. Crescent Ridge Drive The Woodlands, Texas	77381
(Address of Principal Executive Office)	(Zip Code)

Registrant’s telephone number, including area code: (281) 272-9331

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On November 5, 2009, Opexa Therapeutics, Inc. (the “Company”) issued a press release announcing that Neil K. Warma, the Company’s president and chief executive officer, will deliver a corporate presentation at the Merriman Curhan Ford 6th Annual Investor Summit 2009.  The Company’s presentation will take place at 4:40 p.m. (EST) on Tuesday, November 10, 2009 at the Sofitel New York Hotel in New York City. The presentation will include an overview of the company’s ongoing clinical development program for Tovaxin®, the company’s lead therapy for multiple sclerosis.  The presentation will be webcasted and the link to access the audio webcast and presentation will be available at www.opexatherapeutics.com.  

Item 9.01 Financial Statements and Exhibits

(c)  Exhibit 99.1

The following exhibit is to be filed as part of this 8-K:

Exhibit No.	Description
99.1	Press release issued November 5, 2009 relating to presentation at the Merriman Curhan Ford 6th Annual Investor Summit 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		OPEXA THERAPEUTICS, INC.
		By: /s/ Neil K. Warma
		Neil K. Warma
		President and Chief Executive Officer
DATE:	November 5, 2009

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release issued November 5, 2009 relating to presentation at the Merriman Curhan Ford 6th Annual Investor Summit 2009

EX-99.1

Exhibit 99.1

Opexa to Present at the Merriman Curhan Ford 6^th Annual Investor Summit 2009 on November 10, 2009

THE WOODLANDS, Texas--(BUSINESS WIRE)--November 5, 2009--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin^®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa’s president and chief executive officer, will deliver a corporate presentation at the Merriman Curhan Ford 6^th Annual Investor Summit 2009. The conference will be held November 9-10, 2009, at the Sofitel New York Hotel in New York City.

Opexa’s presentation will occur at 4:40 p.m. (EST) on Tuesday, November 10, 2009 and will include an overview of the company’s ongoing clinical development program for Tovaxin, the company’s lead therapy for MS. The presentation will be webcasted and the link to access the audio webcast and presentation will be available at www.opexatherapeutics.com.

About Opexa

Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Company’s leading therapy, Tovaxin^®, is an individualized cellular immunotherapy treatment in Phase IIb clinical development for multiple sclerosis (MS). Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time. Data from the first Phase IIb clinical study showed compelling evidence that Relapsing Remitting MS patients treated with Tovaxin saw overall clinical, MRI, and immunological benefits over the placebo group, including statistical significance for decrease in the Annualized Relapse Rate (ARR), improvement in disability score (EDSS), and improvement in quality of life measures (MSQLI), as well as an excellent safety profile with no serious adverse events related to Tovaxin treatment.

For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com

CONTACT:
Opexa Therapeutics, Inc.
President and CEO
Neil K. Warma, 281-719-3437
nwarma@opexatherapeutics.com